These effects were noted in obese mice and beta(3)-adrenergic receptor knock-out mice, suggesting that AOD-9604s actions are not mediated directly through the beta(3)-adrenergic receptor, a known facilitator of lipolysis
This occurs through multiple mechanisms
Designed to retain the fat-reducing effects of HGH without influencing growth or insulin-like growth factor 1 levels, AOD9604 has gained attention for its potential as an anti-obesity and metabolic treatment
AOD-9604 is sometimes discussed alongside BPC-157 in joint research planning, and historically alongside GH secretagogues like Sermorelin, Ipamorelin, and GHRP-6 in fat-loss research planning
Researchers confirmed this through knockout studies in mice, where animals lacking beta-3 adrenergic receptors showed zero response to AOD 9604, proving the peptide works specifically through this receptor pathway in adipose tissue